Ohio Public Employees Retirement System (OPERS)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.84M | Sell |
28,709
-2,280
| -7% | -$338K | 0.01% | 696 |
|
|
2026
Q1 | $4.08M | Sell |
30,989
-888
| -3% | -$118K | 0.01% | 749 |
|
|
2025
Q4 | $4.52M | Sell |
31,877
-1,079
| -3% | -$156K | 0.01% | 748 |
|
|
2025
Q3 | $4.63M | Buy |
32,956
+239
| +0.7% | +$32.4K | 0.01% | 735 |
|
|
2025
Q2 | $4.11M | Sell |
32,717
-652
| -2% | -$74.8K | 0.01% | 762 |
|
|
2025
Q1 | $3.69M | Sell |
33,369
-7,149
| -18% | -$906K | 0.01% | 785 |
|
|
2024
Q4 | $5.53M | Sell |
40,518
-2,426
| -6% | -$300K | 0.02% | 672 |
|
|
2024
Q3 | $4.95M | Sell |
42,944
-6,046
| -12% | -$829K | 0.02% | 678 |
|
|
2024
Q2 | $6.74M | Buy |
48,990
+1,043
| +2% | +$143K | 0.03% | 492 |
|
|
2024
Q1 | $6.61M | Buy |
47,947
+2,987
| +7% | +$408K | 0.03% | 520 |
|
|
2023
Q4 | $5.92M | Buy |
44,960
+5,449
| +14% | +$627K | 0.02% | 559 |
|
|
2023
Q3 | $4.45M | Sell |
39,511
-4,319
| -10% | -$455K | 0.02% | 626 |
|
|
2023
Q2 | $4.13M | Sell |
43,830
-3,836
| -8% | -$375K | 0.02% | 707 |
|
|
2023
Q1 | $4.83M | Sell |
47,666
-918
| -2% | -$95.5K | 0.02% | 638 |
|
|
2022
Q4 | $5.8M | Buy |
48,584
+1,020
| +2% | +$119K | 0.03% | 547 |
|
|
2022
Q3 | $5.05M | Buy |
47,564
+374
| +0.8% | +$37.9K | 0.02% | 611 |
|
|
2022
Q2 | $4.6M | Sell |
47,190
-1,420
| -3% | -$131K | 0.02% | 661 |
|
|
2022
Q1 | $4.56M | Sell |
48,610
-1,680
| -3% | -$142K | 0.02% | 759 |
|
|
2021
Q4 | $4.28M | Sell |
50,290
-1,926
| -4% | -$177K | 0.01% | 832 |
|
|
2021
Q3 | $5.01M | Sell |
52,216
-1,175
| -2% | -$111K | 0.02% | 744 |
|
|
2021
Q2 | $5.2M | Buy |
53,391
+3,964
| +8% | +$380K | 0.02% | 740 |
|
|
2021
Q1 | $4.81M | Buy |
49,427
+4,223
| +9% | +$443K | 0.02% | 717 |
|
|
2020
Q4 | $4.33M | Buy |
45,204
+8,731
| +24% | +$843K | 0.02% | 683 |
|
|
2020
Q3 | $3.51M | Buy |
36,473
+1,388
| +4% | +$161K | 0.02% | 645 |
|
|
2020
Q2 | $4.28M | Sell |
35,085
-368
| -1% | -$40.7K | 0.02% | 588 |
|
|
2020
Q1 | $3.07M | Buy |
35,453
+4,620
| +15% | +$452K | 0.02% | 662 |
|
|
2019
Q4 | $3.31M | Sell |
30,833
-18,866
| -38% | -$1.98M | 0.02% | 729 |
|
|
2019
Q3 | $4.48M | Buy |
49,699
+27
| +0.1% | +$2.52K | 0.02% | 600 |
|
|
2019
Q2 | $4.19M | Sell |
49,672
-1,195
| -2% | -$98.1K | 0.02% | 639 |
|
|
2019
Q1 | $4.48M | Buy |
50,867
+4,207
| +9% | +$352K | 0.02% | 628 |
|
|
2018
Q4 | $3.33M | Sell |
46,660
-3,376
| -7% | -$323K | 0.02% | 708 |
|
|
2018
Q3 | $6.15M | Sell |
50,036
-1,403
| -3% | -$159K | 0.03% | 538 |
|
|
2018
Q2 | $5.05M | Sell |
51,439
-234
| -0.5% | -$20.9K | 0.03% | 630 |
|
|
2018
Q1 | $4.29M | Buy |
51,673
+14,244
| +38% | +$1.2M | 0.02% | 680 |
|
|
2017
Q4 | $2.9M | Buy |
37,429
+1,881
| +5% | +$128K | 0.01% | 878 |
|
|
2017
Q3 | $2.18M | Sell |
35,548
-1,186
| -3% | -$62.6K | 0.01% | 973 |
|
|
2017
Q2 | $1.69M | Sell |
36,734
-463
| -1% | -$22.5K | 0.01% | 1058 |
|
|
2017
Q1 | $1.61M | Hold |
37,197
| – | – | 0.01% | 1042 |
|
|
2016
Q4 | $1.58M | Sell |
37,197
-32,300
| -46% | -$1.46M | 0.01% | 1052 |
|
|
2016
Q3 | $3.52M | Buy |
69,497
+14,006
| +25% | +$698K | 0.02% | 682 |
|
|
2016
Q2 | $2.52M | Buy |
+55,491
| New | +$2.55M | 0.02% | 742 |
|
Other funds holding NBIX
Ohio Public Employees Retirement System (OPERS)'s NBIX Position: Q2 2026 in Review
Ohio Public Employees Retirement System (OPERS) reduced its Neurocrine Biosciences (NBIX) stake by 7.4% in Q2 2026, selling an estimated $338K and leaving 28,709 shares worth $4.84M. The position accounts for 0.01% of the portfolio, ranked #696.
Ohio Public Employees Retirement System (OPERS) first reported a position in NBIX in Q2 2016 and has held it in 41 quarters since. The position peaked at $6.74M in Q2 2024. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Ohio Public Employees Retirement System (OPERS) held 28,709 shares of Neurocrine Biosciences worth $4.84M as of Q2 2026.
- Ohio Public Employees Retirement System (OPERS) sold 2,280 Neurocrine Biosciences shares in Q2 2026, an estimated $338K.
- Neurocrine Biosciences made up 0.01% of Ohio Public Employees Retirement System (OPERS)'s portfolio in Q2 2026, its #696 holding.
- Ohio Public Employees Retirement System (OPERS) first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 41 quarters since.
- Ohio Public Employees Retirement System (OPERS)'s Neurocrine Biosciences position peaked at $6.74M in Q2 2024.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Ohio Public Employees Retirement System (OPERS)'s 13F filing for Q2 2026, filed 17 Aug 2026.